China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd.
Omicron Covid variant poses greater risk for the unvaccinated, former White House advisor says : Rashtra News STR | NurPhoto | Getty ImagesThe new omicron Covid variant poses a greater risk for the unvaccinated and there's reason to believe that current vaccines are going to be "quite effective," a former White House advisor said Monday."What